RxDoctor Payments DataLook up a doctor →

Andrea Cercek, MD

Medical Oncology · New York, NYNPI 1710201280

Payments from drug & device makers

$17,756,851in general payments, 2019–2025

Across 514 payments — averaging $34,546 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$8M
  • GSK$7.2M
  • Seagen Inc.$2.4M
  • AbbVie$45K
  • Amgen$20K
  • Merck$17K
  • plus $55K from 12 others
$8,645in research payments, 2019–2025

Across 18 payments — averaging $480.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$6K
  • GSK$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$17,756,851 in reported general payments places this provider in the 95th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York

Medicare billing

Part B allowed, 2024
$46,578
Medicare patients
120
Services billed
325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →